Meda Eyes Its Own Deals After Spurning $24B Mylan Tie-Up
Swedish drugmaker Meda AB said Wednesday that it sees itself as a buyer — not a target — and would eye "major acquisitions" to help double its size after twice rebuffing...To view the full article, register now.
Already a subscriber? Click here to view full article